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PSTATE-OF-THE-ART PAPERS
Cardiovascular Magnetic Resonance
in Patients With Myocardial Infarction
Current and Emerging Applications
Han W. Kim, MD,*† Afshin Farzaneh-Far, MD, PHD,*† Raymond J. Kim, MD*†‡
Durham, North Carolina
In patients with known or suspected myocardial infarction (MI), cardiovascular magnetic resonance (CMR) pro-
vides a comprehensive, multifaceted view of the heart. The data, including that from a recent multicenter clini-
cal trial, indicate that delayed-enhancement cardiac magnetic resonance imaging (DE-CMR) is a well-validated,
robust technique that can be easily implemented on scanners that are commonly available worldwide, with an
effectiveness that clearly rivals the best available imaging techniques for the detection and assessment of acute
and chronic MI. When patients present outside the diagnostic window of cardiac troponins, DE-CMR may be es-
pecially useful. Moreover, because DE-CMR can uniquely differentiate between ischemic and various nonisch-
emic forms of myocardial injury, it may be helpful in cases of diagnostic uncertainty, such as in patients with
classical features of MI in whom coronary angiography does not show a culprit lesion. Even after the diagnosis
of MI has been made, CMR provides clinically relevant information by identifying residual viability, microvascular
damage, stunning, and right ventricular infarction. In addition, post-MI sequelae, including left ventricular throm-
bus and pericarditis, are easily identified. Given that quantification of infarct size by DE-CMR is highly reproduc-
ible, this technique may provide a useful surrogate end point for clinical trials with appreciable reductions in
sample size compared with alternative methods. (J Am Coll Cardiol 2010;55:1–16) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.059n
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tyocardial infarction (MI) is a leading cause of death
orldwide (1). Accordingly, preventative and therapeutic
trategies are aimed at reducing its occurrence and adverse
onsequences. New serological biomarkers, such as tro-
onins, have radically improved the diagnosis of MI and
ave enabled the recognition of a group of patients with
mall infarcts, many of whom would not have been identi-
ed in earlier eras (2). Reclassifying this group as patients
ith MI has significant implications (2–4). From an epi-
emiological perspective, a substantial increase in the num-
er of patients diagnosed with MI creates difficulties in
omparing the results of new trials with those of older ones
nd confounds efforts to monitor the impact of public health
easures and treatments. In some clinical trials, the results
ay be significantly altered because the diagnosis of MI can
e used as an entry criterion, an end point, or both. For
ndividual patients, the label of MI can affect a wide range
f issues, including employment, disability claims, insur-
nce, and psychological well-being. Importantly, the diag-
rom the *Duke Cardiovascular Magnetic Resonance Center, †Department of
edicine, and the ‡Department of Radiology, Duke University Medical Center,
urham, North Carolina. Dr. R. J. Kim is an inventor of a U.S. patent on
elayed-enhancement CMR that is owned by Northwestern University, and is a
ofounder of HeartIT, LLC.f
Manuscript received March 9, 2009; revised manuscript received May 26, 2009,
ccepted June 18, 2009.osis of MI also impacts clinical management, and the
vailable data indicate that even small infarcts portend worse
hort- and long-term prognosis (5).
Despite the use of improved biomarkers, the diagnosis of
I can still be difficult. There is marked heterogeneity in
he presentation of MI and significant overlap with other
isorders that result in myocardial injury, such as myocar-
itis and Takotsubo cardiomyopathy. In this context, it is
oteworthy that the latest consensus guidelines defining MI
nclude noninvasive imaging because it may be helpful in
ases of uncertainty (6). The new criteria incorporating
maging evidence of MI involve not only established mo-
alities such as echocardiography and radionuclide imaging,
ut also the newer modalities, cardiovascular magnetic
esonance (CMR) and cardiac computed tomography. In
articular, delayed enhancement (DE)-CMR appears to
ffer advantages in detecting small or subendocardial in-
arcts with high accuracy and is well validated (7–12). Thus,
t is timely to review the role of CMR in the diagnosis and
ssessment of MI. In this article, we examine the utility of
MR in patients with known or suspected MI with
mphasis on the additive clinical information it may pro-
ide. Additionally, there has been growing interest in using
nfarct size measured by CMR as an end point for clinical
rials, and we discuss operational and other relevant issues
or this application.
s
a
c
e
q
q
u
p
o
p
t
o
M
e
a
c
i
a
i
f
c
g
l
a
t
m
v
t
i
o
w
i
2 Kim et al. JACC Vol. 55, No. 1, 2010
CMR in Patients With MI December 29, 2009/January 5, 2010:1–16CMR
Multitechnique imaging. At the
outset, it is important to recognize
that CMR is not a single entity,
but consists of multiple distinct
techniques, each providing sepa-
rate pieces of information. These
different techniques arise from
special software programs, called
pulse sequences, and many inno-
vations in CMR arise as much
from novel pulse sequences as
from advances in hardware. Thus,
with different pulse sequences,
each tuned to highlight specific
biological tissues or properties
(e.g., fat, thrombus, infarction,
chamber blood flow, tissue perfu-
sion, and so on), one can get mul-
tiple data acquisitions of the same
location and obtain a comprehen-
sive, multifaceted view of the heart
(13). Additionally, because many
image artifacts are pulse-sequence
pecific, these are not propagated throughout the examination
nd generally do not reduce overall scan quality (14).
The versatility of CMR, however, results in increased
omplexity. For each pulse sequence there are many param-
ters that need to be set correctly to achieve optimal image
Figure 1 Timeline and Potential Components of a Multitechniqu
2D  2-dimensional; 3D  3-dimensional; CMR  cardiovascular magnetic resona
MI  myocardial infarction; MRA  magnetic resonance angiography; SNR  signa
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CAD  coronary artery
disease
CMR  cardiovascular
magnetic resonance
DE  delayed enhancement
ECG  electrocardiogram
FWHM  full-width at
half-maximum
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
SPECT  single-photon
emission computed
tomography
STEMI  ST-segment
elevation myocardial
infarctionuality. Additionally, it may be unclear which pulse se-
uence or (more commonly) group of sequences should be
sed for a given clinical indication. If a pulse sequence is not
erformed during the scan, the image data cannot be
btained later via post-processing. As a result, standardized
rotocols are useful for ensuring comprehensive examina-
ions (15). Unfortunately, at present, CMR examinations
ften vary among sites, even for specific indications such as
I. The rapid pace of development in pulse sequences
xacerbates this problem.
Figure 1 illustrates many of the components, along with
timeline, of a typical multitechnique CMR protocol for
ardiac imaging. Sequences are added or excluded depend-
ng on the indication, patient considerations (such as the
bility to breath-hold), and even findings during the exam-
nation itself. Generally, all patients undergo cine imaging
or the assessment of morphology, ventricular volumes, and
ontractile function. Delayed-enhancement imaging after
adolinium administration is routinely performed and al-
ows the diagnosis and sizing of MI, assessment of viability,
nd other tissue characterization such as identification of
hrombus and nonischemic scarring. Irregular heart rhythm
ay necessitate the use of single-shot (real-time) sequence
ariants to obtain diagnostic-quality images (16,17). Op-
ional elements include stress perfusion imaging to evaluate
schemia and velocity-encoded imaging for the assessment
f hemodynamics and valvular function. Additionally, T2-
eighted imaging has shown promise in assessing acute,
nflammatory processes such as acute MI or myocarditis, and
R Examination for Cardiac Imaging
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December 29, 2009/January 5, 2010:1–16 CMR in Patients With MIay prove useful in distinguishing chronic lesions from those
f recent onset (18). At experienced centers, coronary magnetic
esonance angiography may be performed to exclude left main
r 3-vessel coronary artery disease (CAD) in selected patients
r to evaluate coronary anomalies (19,20).
Even in a 30- to 45-min examination, there are often a
arge number of data acquisitions (50) using different
echniques across multiple spatial locations. The following
RL (http://dcmrc.duhs.duke.edu/figure/, Online Fig. 1)
hows images from a comprehensive study and highlights the
mportance of side-by-side viewing of different techniques to
llow efficient and accurate interpretation. The strengths and
imitations of each of the different CMR techniques should be
ecognized when considering which to use during the exami-
ation as well as during the interpretation. The levels of
xperimental and clinical validation vary among techniques,
nd some are still undergoing development or lack the robust-
ess necessary for general clinical use. Finally, as with any
rocedure, the risks of CMR must be weighed against the
enefits, and patients with contraindications to magnetic res-
nance imaging or gadolinium contrast, such as those with
acemakers/defibrillators (21) or advanced kidney disease (ow-
ng to the risk of developing nephrogenic systemic fibrosis
22]) are not infrequently encountered.
E. Although several CMR techniques could be used for
he diagnosis of MI, the most accurate and best validated is
E-CMR. The technique is straightforward. It involves
nversion-recovery imaging after intravenous administration
f gadolinium contrast and a 5- to 10-min delay (23,24).
ith appropriate settings, normal myocardium appears
lack or nulled, whereas nonviable regions appear bright or
yperenhanced. The mechanism of hyperenhancement has
ot been fully elucidated, but one has been proposed (25)
hat is based on 2 simple facts. First, in normal myocardium,
ecause myocytes are densely packed, tissue volume is
redominately intracellular (75% to 80%) (26). Second,
adolinium chelates are extracellular agents that cannot
ross intact sarcolemmal membranes (27). It then follows
hat gadolinium distribution volume is small and tissue
oncentration is low in a voxel of normal myocardium. With
cute necrosis (acute MI, myocarditis, and so on), there is
embrane rupture, which allows gadolinium to diffuse into
yocytes. This results in increased gadolinium concentra-
ion (28), shortened T1 relaxation, and thus hyperenhance-
ent. In the chronic setting, scar has replaced necrotic
issue and the interstitial space is expanded. This again leads
o increased gadolinium concentration (28) and hyperen-
ancement. In both acute and chronic settings (and all
tages in between), one can consider viable myocytes as
ctively excluding gadolinium. Thus, the unifying mecha-
ism of hyperenhancement appears to be the absence of
iable myocytes rather than any inherent properties that are
pecific for acute necrosis, collagenous scar, or other forms
f nonviable myocardium (25). In the literature, the tech-
ique of DE imaging is also known as delayed hyperen-
ancement, myocardial delayed enhancement, late gadolin-um enhancement, and simply contrast-enhanced CMR.
oncerning late gadolinium enhancement, we note that
ther T1-shortening contrast media aside from gadolinium
ould show late enhancement.
In animal models, extensive comparisons have shown a
early exact relationship between the size and shape of
nfarcted myocardium by DE-CMR to that of histopathol-
gy (Fig. 2A) (7,8,28–33). Additionally, these studies show
hat DE-CMR can distinguish between reversible and
rreversible injury independent of wall motion, infarct age,
nd reperfusion status. Studies in humans have shown that
nfarct size measured by DE-CMR is closely associated
ith peak cardiac enzyme release (10,34–38) and measure-
ents by positron emission tomography (39,40). DE-CMR
lso appears to be superior to single-photon emission
omputed tomography (SPECT) in detecting subendocar-
ial infarcts and infarcts in nonanterior locations (8,11).
urthermore, the high spatial resolution of DE-CMR
nables visualization of even microinfarctions, involving as
ittle as 1 g of tissue, which may occur during otherwise
uccessful percutaneous coronary intervention (Fig. 2B) (9,10).
A 
B 
HISTOLOGY DE-CMR SPECT 
Patient 1 Patient 2 
Figure 2 MI Visualized by DE-CMR
(A) Comparison of delayed-enhancement (DE)-CMR with histopathology and sin-
gle-photon emission computed tomography (SPECT) in 2 animals with subendo-
cardial MI. Note that the size and shape of hyperenhanced regions by DE-CMR
(blue arrows) match the size and shape of infarcted regions delineated by his-
tological vital staining. No infarcts are evident by SPECT. Modified, with permis-
sion, from Wagner et al. (8). (B) Microinfarction (blue arrows) associated with
successful percutaneous coronary intervention is shown in 2 patients. Red
arrows point to the coronary stents. Modified, with permission, from Ricciardi
et al. (9). Guidelines for DE-CMR parameter adjustments may be found else-
where (14,23–25). Abbreviations as in Figure 1.
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CMR in Patients With MI December 29, 2009/January 5, 2010:1–16Recently, the performance of DE-CMR for the detection
f MI was tested in an international multicenter trial (12).
n total, 282 patients with acute and 284 with chronic
rst-time MI were scanned in 26 centers throughout the
.S., Europe, and South America. The study showed that
he sensitivity of DE-CMR increased with increasing gad-
linium dose, reaching 99% and 94% in acute and chronic
I, respectively, with the 0.3-mmol/kg dose (Fig. 3).
urthermore, with doses 0.2 mmol/kg or higher, when MI
as identified, it was in the correct location in more than
7% of patients (i.e., the location of hyperenhancement
atched the perfusion territory of the infarct-related artery).
mportantly, this study represents the first multicenter trial
esigned to evaluate an imaging approach for detecting MI.
lthough several multicenter trials have used infarct size
easurements by SPECT as a surrogate end point to assess
he efficacy of an investigative therapy (41), these trials were
ot designed to evaluate SPECT, and limited multicenter
ata on the sensitivity or accuracy of radionuclide imaging
or detecting or localizing MI have been reported. In
ddition, the multicenter DE-CMR trial tested the sensi-
ivity of imaging for both acute and chronic MI. This is
otable because there are far fewer clinical trial data on the
etection of chronic MI, and chronic infarcts are generally
ore difficult to detect than acute infarcts because substan-
ial shrinkage can occur during healing (7). Thus, in sum,
he data indicate that DE-CMR is a well-validated, robust
echnique that can be easily implemented on scanners that
re commonly available worldwide, with an effectiveness
hat rivals the best available imaging techniques for the
etection and assessment of MI.
iagnosis and Assessment of MI
ssues in clinical diagnosis. According to the American
ollege of Cardiology/European Society of Cardiology
onsensus document on the universal definition of MI, the
14 
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Figure 3 Sensitivity of DE-CMR for Acute and Chronic MI
The diagnostic sensitivity of detecting MI is summarized according to gadoverseta
Numbers in parentheses are 95% confidence intervals. Modified, with permission,ornerstone tests for the diagnosis are troponins and the
lectrocardiogram (ECG) (6). Unfortunately, these tests
ave some limitations. Although troponin assays are exquis-
tely sensitive and can detect minute amounts of myocardial
ecrosis, levels are elevated for only a few days after an acute
vent (42). Importantly, many patients do not have classic
ymptoms and do not seek medical attention within the
ime window when troponins are elevated. The consequence
s that many subacute and all chronic infarcts will not be
dentified by troponins. The ECG is helpful in this situa-
ion, and incident Q waves have been the basis for diagnos-
ng silent or clinically unrecognized MI in population
tudies (43). These surveys have shown that unrecognized
Is are common, comprising as many as 40% to 60% of all
Is. By definition, however, all unrecognized infarcts that
re non–Q-wave will be missed (44). Additionally, Q waves
ften occur in the setting of nonischemic cardiomyopathy,
nd the specificity of the ECG may be poor in the setting of
ther cardiopulmonary disorders (45).
In these circumstances, cardiac imaging has the potential
o provide corroborative diagnostic information. The uni-
ersal definition indicates that new regional wall motion
bnormalities or a loss of viable myocardium could be
onsidered evidence of MI (6). However, wall motion
bnormalities may not occur unless the infarcted region
xceeds 20% to 50% of the myocardial wall (2,46). Similarly,
cintigraphic defects may not be apparent until 10 g of
issue is infarcted (2). Thus, because a sizable threshold of
amage is required, echocardiography or SPECT may miss
I, particularly when it is small or subendocardial. Con-
ersely, when abnormalities in regional function or perfu-
ion are present, they do not always indicate MI. Both may
e abnormal in the setting of ischemia without infarction.
onischemic conditions, such as cardiomyopathy or inflam-
atory or infiltrative diseases, can also lead to wall motion
bnormalities or loss of viable myocardium. Hence, the
6 
(1-12) 
3 
(0-7) 
8 
(2-15) 
10 
(3-17) 
52 
(40-63) 
83 
(74-91) 
87 
(79-95) 
94 
(89-100) 
44 
(33-52) 
73 
(62-83) 
84 
(76-93) 
92 
(86-99) 
Pre-Contrast Post-10 Mins Post-30 Mins 
0.05 0.1 0.2 0.3 
Dose (mmol/kg) 
Gadoversetamide 
Legend 
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im et al. (12). Abbreviations as in Figures 1 and 2.mide d
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December 29, 2009/January 5, 2010:1–16 CMR in Patients With MIositive predictive value of these imaging findings is not
igh unless these conditions can be excluded (6).
Even some patients who have all of the classic features of
I—for example, chest pain, new ST-segment changes,
nd an increase in troponins—and fulfill the universal
efinition, may ultimately prove not to have had an MI. For
nstance, it is well known that ST-segment changes and
levated troponins can occur in the setting of many disor-
ers, including myocarditis, Takotsubo cardiomyopathy,
rauma, pulmonary embolism, and drug toxicity (6). The
revalence of these disorders is poorly characterized, but
otably, several studies have shown that a nontrivial pro-
ortion of patients with clinically suspected MI have normal
oronary arteries or insignificant disease at angiography,
ncluding up to 10% of patients initially diagnosed with
T-segment elevation myocardial infarction (STEMI) and
2% with acute coronary syndrome (ACS) (Table 1) (47–62).
lthough recanalization after an occlusive coronary event is
ell documented (63,64), many of these patients are un-
ikely to have had an MI, leaving clinicians with unanswered
uestions regarding diagnosis and management.
revalence of Nonobstructive CAD in Patients With MI or ACS UndTable 1 Prevalence of Nonobstructive CAD in Patients With MI
Study Year n*
STEMI
Larson et al. 2007 1,335
DANAMI-2 substudy 2007 516
CAPTIM 2002 405
GUSTO IIb 1999 2,251
NSTEMI
ICTUS substudy 2007 599
CRUSADE 2006 38,301
TACTICS–TIMI 18 substudy 2005 542
FRISC II substudy 2001 1,142‡
GUSTO IIb 1999 1,749
Non–Q-wave MI
VANQWISH substudy 2002 350
NSTEMI and ACS (negative biomarker)
SYNERGY 2007 7,005
Bugiardini et al. 2006 7,656
ISAR-COOL 2003 410
RITA-3 2002 865
PURSUIT 2000 5,767
TIMI IIIB 1994 1,193
STEMI, NSTEMI, and ACS (negative biomarker)
GRACE 2009 26,755
MATE 1998 163
ACS (negative biomarker)
TACTICS–TIMI 18 substudy 2005 353
FRISC II substudy 2001 1,142‡
GUSTO IIb 1999 2,406
Patients who underwent angiography and had data available. †Estimated from patients in angi
xplanation provided. ‡Values reflect the data from the combined group of NSTEMI and ACS with
— data not available; ACS acute coronary syndrome; CAD coronary artery disease; F female; M
TEMI  ST-segment elevation myocardial infarction.mproving diagnosis. In situations such as these, where
he diagnosis of MI by the universal definition is difficult,
E-CMR may prove to be helpful. One emerging appli-
ation has been the identification of unrecognized MI.
mong 195 patients without a history of MI undergoing
linically indicated CMR, Kwong et al. (65) found that the
revalence of unrecognized MI by DE-CMR was 76%
igher than by ECG. Among 185 patients with clinically
uspected CAD who underwent CMR for research pur-
oses (not clinically ordered), Kim et al. (44) reported that
he prevalence of unrecognized MI by DE-CMR was 313%
igher than by ECG. In 259 randomly chosen 70-year-old
esidents of Uppsala, Sweden, Barbier et al. (66) observed a
90% higher rate. In all 3 studies, several patients with
waves did not have hyperenhancement, which probably
eflects the limited specificity of electrocardiography for
iagnosing MI.
From a public health standpoint, the implications of
hese studies may be considerable. It has been estimated that
90,000 patients in the U.S. and perhaps as many as
00,000 in Europe suffer from unrecognized MI annually
ng AngiographyCS Undergoing Angiography
Nonobstructive CAD
No Single Culprit
(None, Multiple) Ref. #tion
Prevalence (%)
Overall M F
% 10 8 14 15% (14%, 1%) 61
% 4 — — — 47
10† — — — 48
8 7 10 — 49
% 9 — — — 50
% 9 6 12 — 51
% 6 4 10 — 52
% 7 4 14 44%‡ 53
5 4 9 — 49
% 6 — — 51% (37%, 14%) 54
8 — — — 55
% 9 — — — 56
% 11 — — — 57
% 22 — — — 58
% 12 — — — 59
% 16 — — — 60
% 8 6 12 — 61
% 25 — — 45% (44%, 1%) 62
% 21 17 28 — 52
% 32 26 43 44%‡ 53
20 14 31 — 49
arm not undergoing percutaneous coronary intervention because of normal coronary flow or no
e biomarker.ergoior A
Defini
50
50
—
—
70
50
50
50
—
50
—
—
50
50
70
50
60
50
70
50
50
—
oplasty
negativmale; MImyocardial infarction; NSTEMI non–ST-segment elevation myocardial infarction;
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CMR in Patients With MI December 29, 2009/January 5, 2010:1–1667,68). Because these estimates reflect only patients iden-
ified by ECG, the DE-CMR studies suggest that the
ctual incidence may be 3-fold higher. However, infarct size
s larger and left ventricular ejection fraction (LVEF) is
ower in patients with unrecognized MI with Q waves than
hose without (44), and one might question whether the
rognosis of individuals with unrecognized MI by DE-
MR is relatively benign. On this point, we note that Kwong
t al. (65) reported that the presence of unrecognized MI by
E-CMR conferred nearly a 6-fold increased risk for major
dverse cardiac events. Likewise, Kim et al. (44) reported that
he presence of unrecognized non–Q-wave MI predicted
n 11-fold higher risk of all-cause mortality than those
ithout MI.
Initial studies suggest that CMR may also be useful in the
mergency department setting for the evaluation of patients
ith chest pain. Kwong et al. (69) showed that a multitech-
ique CMR examination can be performed rapidly and
afely in emergency department patients, and reported that
MR added diagnostic value over standard clinical assess-
ent for the diagnosis of ACS. Cury et al. (70) reported
imilar findings, but also showed that CMR has the
otential to diagnose acute MI even when the first troponin
easurement is negative.
Similar to troponins, the detection of injury by DE-
MR is specific for irreversible myocardial damage but is
ot specific for MI. One potential advantage of DE-CMR
s that the pattern of hyperenhancement, rather than simply
he presence or extent, may offer important information
egarding the etiology of myocardial damage (71–73). For
his purpose, the concept that ischemic myonecrosis pro-
eeds as a wavefront (74) from the subendocardium to the
picardium with increasing coronary occlusion time is cru-
ial. Correspondingly, hyperenhancement patterns that
pare the subendocardium and are limited to the middle or
picardial portion of the left ventricular (LV) wall are
nvariably nonischemic in origin because damage in the
etting of CAD almost always involves the subendocardium
71–73). Moreover, certain nonischemic disorders, such as
yocarditis, have characteristic hyperenhancement patterns
hat suggest specific diagnoses, and a systematic approach to
nterpreting DE-CMR images in patients with cardiomy-
pathy has been proposed (72,75). Figure 4 shows repre-
entative examples of how DE-CMR may be clinically
seful in 3 patients presenting with chest discomfort,
T-segment elevation, and positive troponins. In all 3, the
nitial diagnosis was STEMI, but insignificant CAD was
ound at coronary angiography. DE-CMR was performed
ecause the diagnosis was uncertain, and in each case
rovided information to clarify the diagnosis.
Data regarding the prevalence of the heterogeneous
isorders that may mimic MI are limited. However, re-
ently, Assomull et al. (76) evaluated the role of CMR in 60
atients presenting with chest pain, elevated troponins, and
nobstructed coronary arteries. DE-CMR provided a new
iagnosis in 65% of patients (myocarditis was most com- aon) and excluded significant pathology in the remainder.
n a registry of 1,335 STEMI patients undergoing coronary
A Patient 1 
B Patient 2 
C Patient 3 
Figure 4
Typical DE-CMR Images From 3 Patients With Chest
Discomfort, ST-Segment Elevation,  Troponins, and
Normal Coronary Arteries at Angiography
(A) Linear, mid-myocardial hyperenhancement (red arrows) is present, particu-
larly in the septum, and is indicative of myocarditis. (B) In the setting of sud-
den emotional stress and apical ballooning, the absence of hyperenhancement
is consistent with Takotsubo cardiomyopathy. (C) Focal but transmural hyper-
enhancement (red arrows) involving the lateral apex is present and indicative
of MI because of temporary occlusion of a small diagonal branch off the distal
left anterior descending coronary artery (top). DE-CMR with a long inversion
time (600 ms) shows a thrombus (yellow arrowheads) in the left atrial
appendage (bottom), suggesting that an embolus led to the MI. Abbreviations
as in Figures 1 and 2.ngiography, Larson et al. (77) reported that 14% had no
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December 29, 2009/January 5, 2010:1–16 CMR in Patients With MIulprit artery and 9.5% did not have significant CAD. In the
roup without a clear culprit artery, CMR established that
he most common diagnoses were myocarditis (31%), Tako-
subo cardiomyopathy (31%), and STEMI without an angio-
raphic lesion (29%). Concerning the latter, Table 1 shows
hat in many patients with acute MI or ACS, the culprit artery
annot be identified because of the absence of CAD or the
bsence of typical angiographic characteristics, or because
ultivessel CAD is present and more than 1 artery/culprit
ould be responsible. In these circumstances, by visualizing the
I location, DE-CMR may be helpful in identifying the
nfarct-related artery (Fig. 4C).
mproving infarct characterization and identification of
equelae. Even when the diagnosis of MI is certain, it is
ften useful to further characterize the infarct and identify
equelae. Infarct size can be measured accurately and with a
igh level of reproducibility in both acute and chronic
ettings (32,78,79). Additionally, the high spatial resolution
f DE-CMR allows determination of the transmural extent
Figure 5 MI Characterization and Potential Post-MI Sequelae
Examples are shown of patients with MI complicated by the presence of (A) micro
(red arrows). (C) Acute infarcts (red arrows) can be differentiated from chronic in
acute necrosis (green arrows). (D) Post-MI sequelae such as mural thrombus (blu
detection because the image intensity of viable myocardium is gray rather than bla
Acute pericarditis can be diagnosed by the presence of hyperenhanced pericardium
location (orange stars), extent of associated infarction (red arrows), and severityf infarction, which provides supplemental information to
nfarct size in predicting improvement in contractile func-
ion with mechanical revascularization or medical therapy
35,80–83). DE-CMR may also allow assessment of gra-
ations of injury within acute MI. Rather than simply
dentifying a region of acute infarction as nonviable, DE-
MR can distinguish acute infarcts with only necrotic
yocytes from acute infarcts with necrotic myocytes and
amaged microvasculature (Fig. 5A). The latter is associ-
ted with more severe ischemic injury and results in com-
romised tissue perfusion even after restoration of epicardial
oronary flow. Microvascular damage, also known as the
o-reflow phenomenon, is important to detect because it
ppears to be associated with adverse ventricular remodeling
nd poor clinical outcome (84–87).
Increasing experience with CMR has led to the develop-
ent of new applications that may be used to diagnose
dverse sequelae associated with MI, including right ven-
ricular involvement, acute pericarditis, and LV thrombus
ar damage (no reflow, purple arrows), and (B) right ventricular (RV) involvement
by the use of T2-weighted imaging, which can show increased signal in areas of
ws) can be identified by DE-CMR. Long-inversion-time imaging may improve
rombus is often immediately adjacent to infarcted myocardium (red arrows). (E)
nge arrowheads). (F) CMR image may be used to define ventricular septal defect
nting. T2W  T-2 weighted; other abbreviations as in Figure 2.vascul
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CMR in Patients With MI December 29, 2009/January 5, 2010:1–16Figs. 5B to 5F). In patients with acute inferior MI, Kumar
t al. (88) showed that even when physical examination,
CG with right precordial leads, and echocardiography
ere negative, DE-CMR could detect right ventricular
nvolvement in nearly 25% of patients. Taylor et al. (89)
sed a multitechnique CMR examination to evaluate pa-
ients with pericardial disease. Pericardial hyperenhance-
ent appeared to be both sensitive and specific for inflam-
atory pericarditis, as verified by histopathology, whereas
ericardial thickening without hyperenhancement was con-
istent with a noninflammatory fibrotic pericardium. In
atients with MI or ischemic cardiomyopathy, Mollet et al.
90) reported that DE-CMR identified LV thrombus in
ubstantially more patients than cine-CMR or transthoracic
chocardiography; however, a reference standard was not
vailable. Srichai et al. (91) evaluated a protocol combining
ine- and DE-CMR for the diagnosis of LV thrombus in
atients with advanced ischemic cardiomyopathy undergo-
ng surgical LV reconstruction. Among 160 patients (in
hom there was surgical and/or pathological confirmation
f thrombus), CMR showed higher sensitivity and specific-
ty (88% and 99%, respectively) than transthoracic (23%,
6%) and transesophageal (40%, 96%) echocardiography.
einsaft et al. (92) assessed the prevalence of LV thrombus
y cine and DE-CMR in 784 consecutive patients with
ystolic dysfunction. The DE-CMR detected a higher
revalence than cine-CMR (7.0% vs. 4.7%, p 0.005), and
ollow-up for embolic events or pathological confirmation
as consistent with DE-CMR as the better reference
tandard. Interestingly, patients with ischemic cardiomyop-
thy were 5 times more likely to have thrombus than those
ith nonischemic cardiomyopathy despite similar LVEF.
dditionally, myocardial scarring by DE-CMR was iden-
ified as a novel risk factor for thrombus.
The ability of DE-CMR to identify thrombus based on
issue characteristics rather than just anatomical appearance
ikely explains its improved performance compared with
ine-CMR or noncontrast echocardiography. The basic
nderlying principle is that thrombi are avascular and have
ssentially no gadolinium uptake. Thus, thrombus can be
dentified as a nonenhancing defect surrounded by bright
entricular blood and contrast-enhanced myocardium. Im-
ge intensity differences between normal myocardium and
hrombus can be accentuated by using a DE-CMR se-
uence in which the inversion time is increased to null
vascular tissue such as thrombus (500 to 600 ms) (92).
ith long-inversion-time imaging, regions with contrast
ptake such as viable myocardium increase in image inten-
ity, whereas thrombus appears homogeneously black, and
here is improved delineation, particularly of mural throm-
us (Fig. 5D). The concept that contrast uptake, albeit low,
s not zero in normal myocardium, is one reason why we
refer to describe nonviable regions as hyperenhanced rather
han simply enhanced because depending on the DE-CMR
ettings, viable myocardium can show contrast enhancement
ompared with avascular tissue. DFigure 6 outlines possible CMR findings in patients with
uspected MI. Furthermore, it shows the potential of CMR
o provide additive diagnostic information and how CMR
ay be incorporated with traditional clinical assessment.
MR Infarct Size as a
urrogate End Point for Clinical Trials
he ultimate goal of a new therapy for acute MI is a
eduction in mortality. In the current era, treatment of acute
I is quite effective; therefore, demonstrating a further
eduction in mortality with novel treatments is increasingly
ifficult and necessitates studies with large sample sizes.
his requirement imposes significant logistical and financial
arriers on testing potential new therapies, and correspond-
ngly limits the number of treatments that can be evaluated.
s such, there is considerable interest in using surrogate end
oints to assess the efficacy of acute MI therapies. Infarct
ize is a particularly attractive surrogate end point for several
easons (41,93). First, it is useful in early screening studies
o test whether a new therapy is biologically active. Second,
t can serve as an end point for phase II dose-ranging studies
o test efficacy and/or safety. Third, it may indicate a late
ortality benefit, and thus rationale for performing a
onger-term study, even if an early benefit is not seen. For
nstance, a reduction in infarct size may lead to a long-term
mprovement in ventricular remodeling, a benefit that may
ot be manifest on 30-day mortality rates. Fourth, it can
rovide a mechanism for improvement in outcome, because
rognosis after acute MI is strongly determined by infarct
ize (94,95). Several investigations have reported that infarct
ize measured by DE-CMR is a stronger predictor of
utcome than LVEF and LV volumes (96–98).
hen to measure infarct size. Measurements of infarct
ize in the first few weeks after infarction need to take into
ccount what Reimer and Jennings (74) termed the chang-
ng anatomic reference base of evolving myocardial infarc-
ion. In their pioneering studies, they showed that infarct
olume can almost double during the first few days after
oronary artery occlusion, even in the absence of additional
yocyte death via lethal reperfusion injury or infarct exten-
ion, because of the addition of edema and cellular elements.
n contrast, infarct volume may shrink to 25% of its initial
olume as necrotic muscle is replaced by scar over 4 to 6
eeks.
Using DE-CMR, similar findings have been observed in
ivo in a canine model (Fig. 7) (99,100). Fieno et al. (99)
howed that terminal infarct size at 4 to 8 weeks averaged
4% of that found at 3 days, and reperfusion accelerated
nfarct resorption. Moreover, the mass of viable myocar-
ium increased systematically with time, although the time
ourse of hypertrophy was different from that of infarct
esorption. Importantly, measurements of total LV mass did
ot reflect the changes occurring separately in infarcted and
iable regions. These results highlight the capability of
E-CMR to improve the assessment of post-infarction
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December 29, 2009/January 5, 2010:1–16 CMR in Patients With MIentricular remodeling by allowing evaluation of concurrent
hanges such as resorption of infarcted tissue and hypertro-
hy of viable myocardium at an early time point before
easurements of ventricular volumes and mass have
hanged.
Thus, given the changing anatomic reference base, it is
ritical to define the timing of infarct size measurement after
I. There are both advantages and disadvantages of mea-
uring infarct size early versus late after MI, and these are
isted in Table 2. For any particular study, the chosen time
oint will depend on the question being addressed and the
ogistics of the trial.
ow to measure infarct size on DE-CMR image. Several
ethods have been used for the measurement of DE-CMR
nfarct size. The simplest of these is visual assessment.
yperenhancement is scored on a 17-segment model with a
Suspected STEM
Culprit Lesion Identified 
(+) CAD 
Coronary  Angiograp
(+) (-) 
Aborted MI 
(+) 
MI, multivessel Dz Chronic MI
Abo
Confirmed MI 
•Infarct size (DE) 
•Stunning (cine and DE) 
•“No-reflow” (DE) 
•Possible edema (T2W) 
Potential CM
•No infarct present (DE) 
•Possible stunning (cine) 
•Possible edema (T2W) 
•Identify the infarct location (DE) 
•Determine the IRA (DE) 
•Possible edema (T2W) 
Chronic MI, pe
•identify infar
•absence of 
•LV aneurysm
•absence of 
Aborted MI 
•no infarct pr
•possible stu
•possible ede
Troponin Troponin 
Figure 6 Schema Highlighting the Potential Utility of CMR in P
Suspected STEMI patients often undergo early coronary angiography. When a culprit le
lated, partially recanalized lesion without subsequent troponin elevation indicates an a
edema may be seen. If diffuse multivessel disease is seen along with multiple potent
artery by showing the location of acute necrosis and associated edema. If CAD is pres
chronic MI by CMR indicates the diagnosis of chronic MI with persistent ST-segment e
is suggested. Troponin elevation in the apparent absence of CAD may occur in a num
thrombus, missed ostial side branch occlusion, or pulmonary embolism. Various CMR
vated, CMR may be helpful in identifying pericardial pathology or ruling out acute cardi
hyperenhancement; IRA  infarct-related artery; LBBB  left bundle branch block; LVH
 ST-segment elevation myocardial infarction; T2W  T2-weighted; other abbreviation-point scale for each segment (0  no hyperenhancement, i 1% to 25%, 2  26% to 50%, 3  51% to 75%, 4 
6% to 100%) (16,81). Dark regions entirely encompassed
ithin hyperenhanced myocardium are interpreted as re-
ions of microvascular damage (no-reflow) and included as
art of the infarct. Infarct size as percent LV myocardium is
alculated by summing the regional scores, each weighted by
he hyperenhancement range midpoint (i.e., 1  13%, 2 
8%, 3  63%, 4  88%) and dividing by 17 (12,16). This
ystem allows for rapid assessment of infarct size in incre-
ents of 1.2% of LV mass. Alternatively, infarct size can
e quantified by planimetry of hyperenhanced areas on the
tack of short-axis images.
In an attempt to be more objective, several semiautomatic
ethods have been proposed. Initial studies showed that a
imple image intensity threshold of 2 to 3 SD above the
ean of remote, normal myocardial intensity resulted in
No Single Culprit Lesion 
(-) CAD 
(+) (-) 
tent STE 
I 
Myocarditis 
Takotsubo CM 
Coronary emboli 
Lysis of thrombus 
Missed side branch occlusion 
Pulmonary emboli 
Pericarditis 
Early Repolarization 
LVH 
LBBB 
Brugada syndrome 
lity/Findings 
Pericarditis 
•pericardial HE (DE) 
•effusion (cine) 
•thickening (cine) 
Others 
•no acute CMR findings 
STE 
w” (DE) 
 
T2W) 
E) 
ine) 
W) 
Myocarditis 
•mid-myocardial/epicardial HE (DE) 
•possible edema (T2W) 
Takotsubo CM 
•no HE (DE-CMR) 
•apical ballooning with stunning (cine) 
•possible edema (T2W) 
Coronary emboli 
•CAD pattern HE (DE) 
•possible intracardiac thrombus (DE) 
Lysis of thrombus/side branch 
occlusion 
•CAD pattern HE (DE) 
Pulmonary emboli 
•acute RV dilation/dysfunction (cine) 
Troponin 
ts With Suspected STEMI
identified with an appropriate increase in troponins, then MI is confirmed. An iso-
MI. In this situation, CMR will not show an MI, but myocardial stunning and/or
rit lesions and troponins are elevated, CMR may help identify the infarct-related
t a culprit lesion is not identified and troponins are not elevated, the presence of a
n. If CMR does not detect MI but stunning and/or edema is present, an aborted MI
settings, including myocarditis, Takotsubo cardiomyopathy, coronary emboli, lysis of
s may point to a specific diagnosis. If CAD is absent and troponins are not ele-
hology. CAD  coronary artery disease; CM  cardiomyopathy; Dz  disease; HE 
t ventricular hypertrophy; RV  right ventricular; STE  ST-segment elevation; STEMI
Figures 1 and 2.I 
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CMR in Patients With MI December 29, 2009/January 5, 2010:1–16rovided by histopathology (7,29). However, these were
xperimental studies that validated high-resolution (0.5 
.5  0.5 mm) ex vivo imaging. For imaging in vivo, spatial
esolution is over 100 times worse, cardiac motion can lead
o further blurring, and partial-volume effects can result in
oxels with intermediate image intensity (7). In this situa-
ion, using a 2- to 3-SD threshold may lead to overestima-
ion of infarct size because gray zones, which represent an
dmixture of viable and nonviable myocytes, are incorrectly
ategorized as fully bright and thus 100% infarcted (101).
lthough a higher cutoff could reduce overestimation, this
ethod is highly dependent on the choice of the remote
Figure 7
Time Course of Changes in Infarct
Size, Viable Myocardium, and LV Mass
After Reperfused and Nonreperfused MI
The top (infarct size), middle (viable myocardium), and bottom (left ventricular
[LV] mass) panels show idealized curves based on data from multiple sources
(83,84). Blue lines denote reperfused myocardial infarction (MI), and dashed
red lines show nonreperfused MI. Within the first few days after MI, infarct size
can substantially increase because of the addition of edema and cellular ele-
ments within the necrotic zone. Thereafter, infarct volume can shrink to 25%
of its initial size over the next 4 to 6 weeks as edema is resorbed and necrotic
myocytes are replaced by scar tissue. After 6 weeks, infarct size is relatively
stable. The volume of viable myocardium (e.g., noninfarcted LV mass) corre-
spondingly declines initially, but may increase over the course of infarct healing
because of myocyte hypertrophy. Changes in total LV mass reflect the sum of
changes occurring in infarcted and viable myocardium.one used to calculate the threshold. An alternative method ehat uses a threshold value of 50% of the maximum intensity
ithin the infarct (full-width at half-maximum [FWHM])
ay be more resistant to surface-coil intensity variations and
rovide improved reproducibility (31). Unfortunately, FWHM
ssumes a bright infarct core, and may not be accurate if the
nfarct is homogeneously gray (Fig. 8). Additionally, FWHM
ay be troublesome if there are multiple infarcts and/or the
nfarct is patchy with multiple, separate islands of necrosis.
ore sophisticated algorithms have been proposed that assign
weighting to each voxel depending on its image intensity
102) or use a combination of methods along with regional
eature analysis (103,104). Although promising, these newer
ethods (and many semiautomated methods) are not widely
vailable, have been tested in few patients, and have not been
hown to work equivalently for images from different magnetic
esonance imaging vendors. The latter would be important for
ulticenter trials.
Moreover, these semiautomated methods are not as
bjective as one might think. All require user input to
istinguish bright artifact and/or noise voxels (false-positive
egions) and dark no-reflow voxels (false-negative regions).
ost important, all require manual tracing of the myocar-
ial borders. This is because there are no automated
lgorithms that can reliably distinguish the bright LV cavity
rom the bright endocardial border of the infarct. Indeed,
issue contrast-to-noise ratio is far lower between infarct
nd LV cavity than between infarct and normal myocardium
16,105). Because the endocardial border may constitute up
o 50% of the infarct perimeter, this portion of the infarct
order may be the largest source of variability in infarct size
easurements. Given these issues, we prefer to planimeter
he infarct visually in our core laboratory using experienced
eaders who can carefully segment myocardial borders and
an account for artifacts, no-reflow regions, and areas with
ntermediate image intensity. Several laboratories have
hown low intraobserver and interobserver variability in
uantifying infarct size visually using experienced readers
44,79,101,106).
ample size considerations. When testing new therapies
sing infarct size as a surrogate end point, sample size (n)
alculations are based on the following formula:
n
2(2)(z⁄2 z)
2
2
here  is the standard deviation of infarct size,  is the
xpected reduction in infarct size due to the new therapy,
nd z is the value of the z-statistic depending on the alpha
nd beta levels set by the study design. Thus, sample size is
etermined by both the expected effect of the therapy ()
nd the variability of measured infarct size within a popu-
ation () (107). The latter is comprised of 2 components:
he variability in infarct size between patients (T) and the
eproducibility (e) of the sizing method (e.g., standard
rror of the measurement).
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December 29, 2009/January 5, 2010:1–16 CMR in Patients With MISeveral studies have now been published that show that
he measurement of infarct size by DE-CMR is highly
eproducible (32,78,79,106). For example, in a 3-center
tudy of patients with acute MI undergoing paired DE-
MR scans, the SD (e.g., e) in repeated measurements was
nly 1% of LV mass (32). The implication of improved
eproducibility is that DE-CMR enables the systematic
A  Dense Infarct 
2 SD above remote 5 SD above remo
44%* 42%*Infarct Size
2 SD above remote 5 SD above remo
B  Diffuse Infarct 
33%* 5%*Infarct Size
Figure 8 Comparison of Methods for the Quantification of Infar
Examples are shown when infarct size is quantified using 4 different methods whe
a user to manually contour epicardial and endocardial contours. Note that when th
result in infarct size measurements that are quite similar. When the infarct is diffu
above remote often results in overestimation of infarct size because the entire are
underestimate infarct size if gray zones are incorrectly assumed to be 100% viable
all pixels above a threshold value of 50% of the maximum intensity within the infa
infarct size. We prefer to planimeter the infarct visually, but will correct for partial
ume analysis methods weight each voxel within the infarct based on the highest s
after user input to remove noise pixels that are beyond the chosen cutoff but are
easurement of Infarct Size: Early Versus LateTable 2 Measurement of Infarct Size: Early Versus Late
Early (<7 to 10 Days)
Advantages
Larger infarct size
Higher detection rate
May reduce required sample size
Can also assess presence and extent of no reflow
Can also assess presence and extent of stunning
Disadvantages
Infarct size is dynamic
Imaging time frame must be narrow (3 days)
Requires patient stability
VEF  left ventricular ejection fraction; MI  myocardial infarction.etection of smaller changes in infarct size, and potentially
llows substantial reduction in sample size for clinical trials.
owever, it has been suggested that this presumes that
aired imaging is performed to detect a change in infarct
ize over time, in which the variability in infarct size
etween patients (T) is eliminated (41). Unfortunately,
aired testing is not feasible in most acute MI trials, and
Full width at half max
Visual planimetry with 
partial volume correction
40%42%
Full width at half max
30%
Visual planimetry with 
partial volume correction
18%
e
the infarct is dense, and (B) the infarct is diffuse. Currently, all methods require
rct is dense and image intensity is homogeneously bright, the various methods
d image intensity is homogeneously gray, using a simple threshold of 2 SD
is gray is incorrectly assumed to be 100% infarcted. Higher thresholds may
full width at half maximum (FWHM) method quantifies infarct size by measuring
the infarct is diffuse and there is no dense core, FWHM can also overestimate
effects by accounting for voxels with intermediate image intensity. Partial vol-
ntensity within the infarct or the blood cavity (whichever is greater). *Infarct size
sly not within the infarcted region.
Late (>4 Weeks)
Infarct size is stable
Imaging time frame can be wide
Can also assess LVEF, which is stable (stunning, if present, has resolved)
Can also assess recovery of function
Can also assess early ventricular remodeling
Presumes survival and successful follow-up
Smaller infarct size
May increase required sample size
Infarct healing (shrinkage) may preclude detection of very small MIte
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CMR in Patients With MI December 29, 2009/January 5, 2010:1–16nfarct size is only assessed after the treatment being tested
as been given (unpaired). Thus, because the variability in
rue infarct size among patients is typically larger than the
ariability added by the infarct sizing method (e.g.,
T  e), it is possible that the improved reproducibility of
E-CMR may not translate into significant reductions in
ample size (41).
To examine this issue further, Figure 9A illustrates the effect
n sample size by changing either the overall variability in
nfarct size, the treatment effect, or both, given typical values
or constants. These calculations show that, for a given treat-
ent effect, even a small decrease in the SD of infarct size, such
s 2% of LV mass, would result in a 20% to 30% reduction in
ample size for each treatment arm. Figure 9B relates percent
hanges in the SD of infarct size to percent changes in sample
ize. For relatively modest decreases in infarct size variability,
he plot shows a nearly 2-to-1 linear decrease in sample size.
or instance, a decrease in variability by 10% results in a 19%
Figure 9 Sample Size Calculations
(A) Sample size per group depending on the expected SD of infarct size and expected
appreciable reductions in sample size. Calculations assume mean infarct size of 13.1
siderations section for further details. (B) Percent decrease in sample size associated
 2) for modest decreases in infarct size variability. Calculations assume mean infarc
See the Sample Size Considerations section for further details.eduction in sample size. hVery few studies have directly compared infarct size mea-
urements by DE-CMR to that by technetium-99m SPECT,
lthough the latter is considered one of the best available
echniques for the quantification of infarct size (41). Mahr-
oldt et al. (78) reported that the SD of infarct size was 6% by
E-CMR and 7.5% by SPECT in a population with chronic
I. Because DE-CMR led to a 20% reduction in variability
1.5 of 7.5), this would result in nearly a 40% reduction in
ample size. Similarly, in patients with acute MI, Ibrahim et al.
108) observed that the SD of infarct size by DE-CMR was
3% lower than SPECT (13 vs. 15, respectively). Lunde et al.
109) evaluated infarct size in STEMI patients randomized to
ntracoronary injection of mononuclear bone marrow cells at
oth acute and chronic time points. In the control group, both
arly and late after MI, the SD of infarct size was lower by
E-CMR than by SPECT (14.0 vs. 21.1 and 12.5 vs. 20.9,
espectively). Although the variability of infarct size will
hange with the population being studied (e.g., cohorts with a
es in treatment effect. Even small decreases in infarct size variability result in
ft ventricular (LV) myocardium,   0.05, and   0.2. See the Sample Size Con-
ercent decrease in SD of infarct size. The relationship is relatively linear (with slope
of 13.1% of LV myocardium, a constant treatment effect,   0.05, and   0.2.chang
% of le
with p
t sizeigh prevalence of anterior MI will have larger mean infarct
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December 29, 2009/January 5, 2010:1–16 CMR in Patients With MIize and larger SD), these data suggest that total variability is
maller when utilizing DE-CMR and will lead to appreciable
ifferences in sample size. As a result, interest in DE-CMR
or infarct size quantification is rapidly growing. When the
linicalTrials.gov registry is searched using the term “infarct
ize,” a total of 110 studies are listed. Of these, 47 do not
nvolve acute MI (e.g., cerebral infarction) or do not explicitly
etail the methodology of measuring infarct size. Of the
emaining 63 studies, 38 (60%) have incorporated DE-CMR
s an end point (110). Additionally, several randomized trials
sing infarct size by DE-CMR as a surrogate end point have
een recently published (109,111–114).
ummary
n patients with known or suspected MI, CMR provides a
omprehensive, multifaceted view of the heart. The data,
ncluding those from a recent multicenter clinical trial,
ndicate that DE-CMR is a well-validated, robust tech-
ique that can be easily implemented on scanners that are
ommonly available worldwide, with an effectiveness that
ivals the best available imaging techniques for the detection
nd assessment of acute and chronic MI. A DE-CMR may
e especially useful when patients present outside the
iagnostic window of troponins. Moreover, because DE-
MR can uniquely differentiate between ischemic and
arious nonischemic forms of injury, it may be helpful in
ases of diagnostic uncertainty, such as in patients with
lassical features of MI in whom coronary angiography does
ot show a culprit lesion. Even after the diagnosis of MI has
een made, CMR can provide clinically relevant informa-
ion with regard to identification of post-MI sequelae and
urther infarct characterization. The high accuracy and
eproducibility of DE-CMR has led to the increasing use of
his technique as the preferred method for quantification of
nfarct size in many clinical trials.
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